SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Tumor Angiogenesis and Immune Modulation

Executive Summary: SU5416 (Semaxanib, SKU A3847) is a potent, selective inhibitor of VEGFR2 (Flk-1/KDR) tyrosine kinase, effectively blocking VEGF-induced endothelial proliferation and angiogenesis in preclinical models (APExBIO). It demonstrates low-nanomolar IC₅₀ values for VEGFR2 inhibition in HUVEC assays (0.04±0.02 μM) and suppresses tumor vascularization and growth in mouse xenograft models at 1–25 mg/kg i.p. dosing (Peng Zhang et al., 2024). SU5416 also functions as an aryl hydrocarbon receptor (AHR) agonist, modulating immune pathways through IDO induction and regulatory T cell differentiation. Its solubility profile (≥11.9 mg/mL in DMSO) allows robust integration into diverse in vitro and in vivo workflows. The compound is widely cited as a benchmark tool for dissecting angiogenesis and immune modulation mechanisms (see related review).

Biological Rationale

Angiogenesis, the formation of new blood vessels, is critical for tumor growth and metastasis. Vascular endothelial growth factor (VEGF) signaling via the VEGFR2 (Flk-1/KDR) receptor tyrosine kinase is a central driver of endothelial proliferation and vascular sprouting (Peng Zhang et al., 2024). Inhibition of this pathway disrupts tumor vascularization, limiting oxygen and nutrient supply to cancer cells. SU5416, also known as Semaxanib, was developed to provide potent, selective blockade of VEGFR2, enabling mechanistic studies in cancer biology, angiogenesis, and vascular remodeling (APExBIO). Notably, SU5416’s activity extends to immune modulation via AHR agonism, linking vascular and immunological research domains (see related review for extended context).

Mechanism of Action of SU5416 (Semaxanib) VEGFR2 inhibitor

SU5416 is a small molecule inhibitor that binds to the ATP-binding pocket of VEGFR2 (Flk-1/KDR) tyrosine kinase. This prevents VEGF-induced receptor phosphorylation, thereby halting downstream signaling cascades required for endothelial cell proliferation, migration, and tube formation (Peng Zhang et al., 2024). The blockade of VEGFR2 signaling results in reduced angiogenesis and tumor vessel formation. Additionally, SU5416 acts as an agonist of the aryl hydrocarbon receptor (AHR), which induces indoleamine 2,3-dioxygenase (IDO) expression. This pathway promotes regulatory T cell (Treg) differentiation and modulates immune responses, with implications for both tumor immune evasion and autoimmune disease models (see advanced insights).

Evidence & Benchmarks

• SU5416 inhibits VEGF-induced mitogenesis in HUVEC cells with an IC₅₀ of 0.04±0.02 μM under standard serum-free conditions (APExBIO, product page).
• In vivo, a single 20 mg/kg intraperitoneal injection of SU5416, followed by 3 weeks of hypoxia, reliably induces pulmonary hypertension in rat models (Peng Zhang et al., 2024, DOI).
• Repeated daily administration at 1–25 mg/kg i.p. significantly suppresses tumor growth in mouse xenografts without mortality at higher doses (DOI).
• SU5416 demonstrates solubility of ≥11.9 mg/mL in DMSO; it is insoluble in ethanol and water, allowing for concentrated stock solutions (APExBIO, SKU A3847).
• SU5416’s AHR agonism leads to increased expression of IDO and regulatory T cell differentiation, supporting its use in immune modulation studies (see advanced insights).

Applications, Limits & Misconceptions

SU5416 is widely used as a reference VEGFR2 inhibitor in angiogenesis and cancer biology experiments. It enables precise dissection of VEGF signaling in both in vitro (e.g., HUVEC proliferation, tube formation assays) and in vivo (tumor xenograft, pulmonary hypertension) models. The compound’s immune modulation profile, via AHR and IDO, expands its utility to autoimmunity and transplant tolerance research. For detailed assay integration, see the article Enhancing Assay Reliability with SU5416, which this article extends by offering updated benchmarks and clarifying immune applications.

Common Pitfalls or Misconceptions

• SU5416 is not effective against VEGFR1 or VEGFR3 at concentrations selective for VEGFR2; off-target inhibition requires higher, often cytotoxic, doses.
• It is insoluble in water and ethanol; preparation in DMSO is essential for reproducible results (APExBIO).
• Observed efficacy in pulmonary hypertension models is context-dependent; not all forms of PH or tumor models respond equally (Peng Zhang et al., 2024).
• SU5416’s AHR-mediated immune effects may confound interpretation in immuno-oncology settings; proper controls are required.
• Long-term storage outside of -20°C or repeated freeze-thaw cycles can degrade compound potency.

Workflow Integration & Parameters

For in vitro studies, SU5416 is typically used at 0.01–100 μM in serum-free or low-serum conditions. Stock solutions should be prepared in DMSO, gently warmed to 37°C or sonicated to enhance dissolution. Aliquots stored at -20°C remain stable for several months. For in vivo applications, dosing regimens of 1–25 mg/kg intraperitoneally are standard, with experimental endpoints defined by model (e.g., tumor volume, pulmonary artery pressure). APExBIO’s A3847 kit provides compound quality assurance for reproducibility. For extended optimization and troubleshooting, this article updates guidance provided in Enhancing Assay Reliability with SU5416.

Conclusion & Outlook

SU5416 (Semaxanib) remains a gold-standard tool for dissecting VEGFR2-dependent angiogenesis and tumor vascularization in cancer research. Its dual role as a VEGFR2 inhibitor and AHR agonist broadens its relevance to immune modulation studies. As translational research advances, SU5416’s well-characterized benchmarks, robust solubility, and established protocols—provided by APExBIO—enable high-confidence experimental design and reliable data generation. For further mechanistic perspectives, see Advanced Insights in Vascular Remodeling and Immune Modulation, which this article extends by clarifying direct benchmarks and practical workflow integration.